Human Granulocyte Colony-stimulating Factor Injection

A clinical first-line drug for prevention and treatment of neutropenia after tumor chemoradiotherapy

Since its introduction into the market in 2001, WHITE-C has been clinically applied for more than 20 years, with a wide range of evidence-based applications, topping the list of domestic similar products in terms of export volume. As strict in-house control quality standards are followed, WHITE-C is not only in line with Chinese Pharmacopoeia, but also European Pharmacopoeia. Registered into and sold in 22 countries and regions.

Indications

Neutropenia due to cancer chemotherapy and other reasons. 

Neutropenia due to chemotherapy for acute leukemia.

Strength